Poster Presentations

Autor: A. Mitra, S. A. Walker, I. Bayer, B. Pickovsky, S. M. Cohen, S. L. Schmitt, F. L. Lucas, S. D. Wexner, E. J. Szilagy, J. B. Ryan, J. G. Williams, K. I. Deen, E. Grant, D. Kumar, O. H. Wiltz, J. E. Garcia, R. Feliciano, J. Martino, M. Solomon, R. S. McLeod, B. O'Connor, H. Steinhart, G. Greenberg, Z. Cohen, A. P. Meagher, W. J. Adams, D. Z. Lubowski, C. N. Ellis, H. W. Boggs, D. J. Coyle, W. S. Blakemore, S. C. Nahas, R. El Ibrahim, H. W. Pinotti, K. Palakanis, J. DeNobile, B. Sweeney, C. Blankenship, J. H. Sun, G. V. Stiegmann, J. G. Kim, N. W. Pearlman, R. V. Landes, R. C. Hankin, D. C. Barkel, W. L. Beauregard, M. D. Poulik, J. C. Chen, C. Dmuchowski, E. Cho, P. Y. Lee, W. S. Fletcher, E. S. Sullivan, J. T. Vetto, T. L. Hull, I. C. Lavery, J. P. Saxton, J. McCue, J. Sheffield, R. Phillips, J. DiPierro, J. W. Milsom, V. W. Fazio, S. A. Strong, A. M. Vernava, W. E. Longo, T. P. Wade, K. S. Virgo, M. A. Coplin, F. E. Johnson, E. Cavina, C. Menconi, G. Ghiselli, M. Seccia, J. J. Tjandra, R. Lowndes, H. McKirdy, T. Schroeder, L. E. Hughes, S. M. Sentovich, L. J. Rivela, A. G. Thorson, G. J. Blatchford, M. A. Christensen, L. L. Jensen, A. C. Lowry, R. Miller, A. Mills, P. Durdey, D. Hock-Saive, R. Lombard, C. Jehaes, S. Markiewicz, L. Penders, F. Fontaine, P. Cusumano, G. Nelissen, A. MacDonald, J. N. Baxter, R. G. Bessent, H. W. Gray, I. G. Finlay, G. S. Duthie, R. Farouk, D. C. C. Bartolo, P. S. Ramanujam, K. S. Venkatesh, G. C. Oliver, D. Vachon, T. E. Eisenstat, R. J. Rubin, E. P. Salvati, K. R. Dorsey-Tyler, G. Harmon, S. J. Medwell, S. R. Binderow, J. J. Noguerás, D. G. Jagelman, C. Decanini, B. Bohm, V. W. Stolfi, P. A. Cataldo, C. Hadick, P. Resnikov, J. D. Mellinger, B. Cunningham, A. J. Vayer, S. W. Larach, P. R. Williamson, A. Ferrara, M. Salomon, J. J. Nogueras, J. Sullivan, R. J. Staniunas, J. O. Keck, T. Counihan, P. Marcello, R. C. Barrett, M. Oster, P. L. Roberts, D. J. Schoetz, J. J. Murray, M. C. Veidenheimer, J. A. Coller, P. M. Sagar, W. Lewis, M. Williamson, P. J. Holdsworth, D. Johnston, J. M. N. Jorge, P. J. Morgado, K. James, P. Morgado, C. Penna, A. Kartheuser, E. Tiret, R. Parc, P. B. McIntyre, J. H. Pemberton, B. G. Wolff, R. R. Dozois, R. W. Beart, K. A. Kelley, J. B. Harrison, S. E. Hockenberry, M. E. R. Williamson, W. G. Lewis, P. Sagar, D. N. Armstrong, B. C. Collopy, P. J. Ryan, R. Fink, J. R. Mackay, R. J. Woods, H. K. Nazarian, L. B. Kong, P. R. Fleshner, M. R. B. Keighley, N. Farmakis, R. Tudor, O. Wiltz, W. D. Wong, S. M. Goldberg, D. A. Rothenberger, M. W. Arnold, S. Schneebaum, E. W. Martin, D. C. Young, S. Schechter, M. L. Snyder, B. A. Orkin, L. E. Smith, P. A. Dean, P. S. Ramsey, H. Nelson, G. Barker, J. P. Neoptolomos, R. T. Patel, A. Pall, D. Adu

Publikováno v: Diseases of the Colon & Rectum. 36:23-41

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::45f3b3a059800a47951bae2de2dc31ae
https://doi.org/10.1007/bf02053959

A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group study

Autor: V K, Sondak, P Y, Liu, L E, Flaherty, W S, Fletcher, P, Periman, D R, Gandara, S A, Taylor, S P, Balcerzak, F L, Meyskens

Publikováno v: The cancer journal from Scientific American. 5(1)

Interferon alfa has modest but definite activity in the treatment of metastatic melanoma and is the only agent currently available for adjuvant therapy of high-risk resected disease. A variety of retinoic acid derivatives have been shown to be synerg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::83bdfc0c7ab5074e6393eee6e62c5930
https://pubmed.ncbi.nlm.nih.gov/10188060

Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group

Autor: V K, Sondak, K J, Kopecky, P Y, Liu, W S, Fletcher, W H, Harvey, L R, Laufman

Publikováno v: Anti-cancer drugs. 5(2)

Didemnin B is a cyclic peptide isolated from the marine tunicate Trididemnin cyanophorum. It is a known potent inhibitor of RNA, DNA and protein synthesis, with activity against the murine B16 melanoma. Fourteen patients with disseminated malignant m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2f3ea0242e3ad5203f3d0015cd3b8427
https://pubmed.ncbi.nlm.nih.gov/8049497

Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study

Autor: A J, Wozniak, B A, Blumenstein, E D, Crawford, M, Boileau, S E, Rivkin, W S, Fletcher

Publikováno v: Cancer. 71(12)

Hormone-refractory metastatic prostate cancer remains a therapeutic challenge. Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF), a drug combination that is active in solid tumors, was evaluated using specific response criteria.Fifty-two eligi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::baecf0fcfcf4751469e6e683e7ea975f
https://pubmed.ncbi.nlm.nih.gov/8508363

Effect of somatostatin analog on peptide release and tumor growth in the Zollinger-Ellison syndrome

Autor: E, Mozell, E A, Woltering, T M, O'Dorisio, W S, Fletcher, A J, Sinclair, D, Hill

Publikováno v: Surgery, gynecologyobstetrics. 170(6)

The clinical presentation of Zollinger-Ellison syndrome (ZES) is the result of gastrin hypersecretion and may be modified by secondary peptide hypersecretion. Treatment is medical (H2-blockers) or surgical (tumor excision and total gastrectomy). H2-b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::09ee616f0331bdf7bacb49e8acfc8338
https://pubmed.ncbi.nlm.nih.gov/2188384